DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Buspirone as a Candidate Medication for Methamphetamine Abuse

Information source: University of Kentucky
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Methamphetamine Dependence; Methamphetamine Abuse

Intervention: Methamphetamine (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: University of Kentucky

Overall contact:
Craig R Rush, Ph.D., Phone: 859-257-5388, Email: crush2@email.uky.edu

Summary

Methamphetamine use disorders are an unrelenting public health concern. Intensive research efforts have yielded behavioral interventions that reduce methamphetamine use, however, these interventions are not universally effective and treatment effects diminish over time. Development of a pharmacotherapy that enhances the efficacy of these interventions is a priority for the National Institute on Drug Abuse. This study proposes to determine the impact of buspirone maintenance on self-administration of methamphetamine. These preliminary data will be used to support further research developing buspirone as a pharmacotherapy for methamphetamine use disorders. The investigators hypothesize that buspirone will attenuate the reinforcing effects of methamphetamine.

Clinical Details

Official title: Buspirone as a Candidate Medication for Methamphetamine Abuse

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science

Primary outcome:

Reinforcing Effects of Methamphetamine During Buspirone Treatment

Reinforcing Effects of Methamphetamine During Placebo Treatment

Secondary outcome:

Subjective Effects

Physiological and Side Effects

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Lifetime methamphetamine use

Exclusion Criteria:

- Abnormal screening outcome (e. g., ECG, blood chemistry result) that study physicians

deem clinically significant

- Current or past histories of substance abuse or dependence that are deemed by the

study physicians to interfere with study completion

- History of serious physical disease, current physical disease, impaired

cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation

- Females not currently using effective birth control

- Contraindications to methamphetamine or buspirone

Locations and Contacts

Craig R Rush, Ph.D., Phone: 859-257-5388, Email: crush2@email.uky.edu

University of Kentucky Medical Center, Lexington, Kentucky 40536, United States; Recruiting
William W Stoops, Ph.D., Phone: 859-257-5388, Email: william.stoops@uky.edu
Craig R Rush, Ph.D., Principal Investigator
Additional Information

Starting date: April 2013
Last updated: May 11, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017